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Hypoxia is an important determinant for biological behavior of malignant solid tu-
mors. In vitro and in vivo studies have shown that tumor hypoxia is associated with in-
creased likelihood of local recurrence and distant metastasis, as well as resistance to ra-
diation therapy and certain types of chemotherapy (1). Preclinical studies have shown
that some copper bis-thiosemicarbazones, especially Cu-ATSM, accumulate avidly in hy-
poxic cells, but are washed out rapidly from normoxic cells.
Copper offers a unique selection of radioisotopes (60Cu, 61Cu, 62Cu, 64Cu, and 67Cu)
with half-lives ranging from 9.8 minutes to 61.9 hours, suitable for imaging and/or ra-
diotherapy (2). The most commonly used copper radioisotopes, 62Cu and 64Cu, provide
very good physical properties for therapeutic and/or diagnostic purposes. Copper-62 is
usually provided by a 62Zn/62Cu generator, but has a short half life of 8 minutes (3).
Copper-64 is used for diagnostic imaging as well as therapy (4).
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[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu]
ATSM) was prepared using in house-made diacetyl-bis(N4-
-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2
produced via the natZn(p,x)61Cu (180 mA proton irradia-
tion, 22 MeV, 3.2 h) and purified by a ion chromatogra-
phy method. [61Cu]ATSM radiochemical purity was >98
%, as shown by HPLC and RTLC methods. [61Cu]ATSM
was administered into normal and tumor bearing rodents
for up to 210 minutes, followed by biodistribution and
co-incidence imaging studies. Significant tumor/non-tu-
mor accumulation was observed either by animal sacrifi-
cation or imaging. [61Cu]ATSM is a positron emission to-
mography (PET) radiotracer for tumor hypoxia imaging.
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Copper-61 is a positron emitter (t1/2 = 3.33 h, b+: 62 %, EC: 38 %), with excellent po-
tentials for application in the PET method and molecular imaging (5). Few production
methods of copper-61 have been reported for radiolabeling of biomolecules and other
applications (6). Interestingly, it has been shown that the tomographic images obtained
using 61Cu are superior to those using 64Cu, based on the larger abundance of positrons
emitted by 61Cu compared to 64Cu (62 % vs. 18 %) (7). As an example of copper-labeled
radiopharmaceutical, Cu-ATSM has been used as a PET hypoxia tracer for oncolo-
gic/cardiologic studies (8, 9).
Based on the interesting properties of copper-61 and the possibility of its production
via natZn(p,x)61Cu, we have already reported a production method (10), and in continua-
tion of this work we hereby report the preclinical studies of [61Cu]ATSM as an imaging
agent in normal rodents and animals with hypoxic tumors.
EXPERIMENTAL
Materials and procedures
Production of 61Cu was performed at the Agriculture, Medicine and Industrial Re-
search School (AMIRS, Karaj, Iran), using a 30 MeV cyclotron (Cyclone-30, IBA, Belgium).
Natural zinc chloride with high purity of more than 98 % was provided commercially
(Merck, Germany). All chemicals were purchased from Sigma-Aldrich Chemical Co. Ra-
dio-chromatography was performed by counting polymer-backed silica gel paper thin
layer sheets using a thin layer chromatography scanner, Bioscan AR2000 (Bioscan, Fran-
ce). Analytical HPLC to determine the specific activity was performed using a Shimadzu
LC-10AT (Japan), armed with two detector systems, a flow scintillation analyzer (Pac-
kard-150 TR, USA) and UV-visible (Shimadzu), using Whatman Partisphere C-18 column
250 ´ 4.6 mm (Whatman Co., USA). Eluent was H2O : CH3CN (1:1), flow rate = 1 mL min–1.
All calculations and RTLC counting were 283 keV peak based. All values were expre-
ssed as mean ± standard deviation and the data were compared using Student’s t-test.
Animal studies were performed in accordance with the United Kingdom Biological Co-
uncil’s Guidelines on the Use of Living Animals in Scientific Investigations. Approval of
the AMIRS Ethical Committee was obtained for the research.
Zinc targetry and bombardment
The target was a layer of natural zinc, electroplated on a copper plate coated with a
50-mm gold layer to prevent interference of the backing copper during radiochemical
separation. Cross section calculations by the ALICE nuclear code (11) showed that the
best proton energy range for natZn(p,x)61Cu reaction was 22–12 MeV. The target had to
be thick enough to reduce the proton energy from 22 MeV to about 12 MeV. The targets
were irradiated in a glancing angle of 6° to achieve a higher production yield. Stopping
and Range of Ions in Matter (SRIM) code (12) was run to determine the best target thick-
ness in the energy range.
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Gold and zinc electrodeposition
A gold-containing bath was prepared according to ref. 13 with slight modifications.
As the 6° glancing angle reduces the required target thickness by 10 fold, electroplating
a 75-mm thick target is good enough. The target was irradiated by 22 MeV (150 mA) pro-
tons for 76 minutes.
Chemical separation
Chemical separation was carried out in no-carrier-added form. The irradiated target
was dissolved in 10 mol L–1 HCl (15 mL, H2O2 added). The solution was passed through
a cation exchange resin (AG 50 W, H+ form, mesh 200–400, 1.3 ´ 10 cm), which had been
preconditioned by passing 25 mL of 9 mol L–1 HCl. The column was then washed by 25
mL of 9 mol L–1 HCl at a rate of 1 mL min–1 to remove copper and zinc ions. Water (30
mL) was added to the eluent to about 100 mL of a 6 mol L–1 HCl solution. The latter so-
lution was loaded on another exchange resin (AG1X8 Cl– form, 100–200 mesh, 25 ´ 1.7
cm) pretreated with 6 mol L–1 HCl (100 mL). Finally, 61Cu was eluted using 2 mol L–1
HCl (50 mL) in the form of [61Cu]CuCl2. The whole process took about 60 min (14).
Quality control of the product
Gamma spectroscopy of the final sample was carried out by a high purity germa-
nium (HPGe) detector coupled with a CanberraTM multi-channel analyzer (Canberra, USA).
The peaks were observed and the area under the curve was counted for 4 hours. Forma-
tion of the colored dithizone-zinc complex was measured using a visible spectroscopic
assay to determine the zinc cation concentration (15). The amount of gold cation in the
final solution was checked using color formation with an acidic rhodamine B reagent re-
acting with gold dilutions based on a previously reported colorimetric method (15).
Preparation of [61Cu]diacetyl-bis(N4-methylthio-semicarbazone)([61Cu]ATSM)
[61Cu]ATSM was prepared starting from H2ATSM and copper acetate (16). H2ATSM
was prepared according to the reported method with modifications (12, 17). Briefly,
[61Cu]CuCl2 (370 MBq) dissolved in acidic medium obtained above (about 2 mL) was
transferred to a 5 mL-vial containing 3 mol L–1 sodium acetate (4 mL) to prepare a
[64Cu]copper acetate solution. A mixture of ATSM (4 mg) in anhydrous DMSO (0.1 mL)
was added to the copper acetate solution and vortexed at 50 °C for 1 min. The mixture
(about 5 mL) was then cooled in an ice bath, and rapidly injected into a C18 Sep-Pak col-
umn pretreated with 5 mL of ethanol and 2 mL of water. The column was washed with
water (4 mL) and purged with a stream of dry N2. The labeled compound was finally
eluted using 0.2-mL portions of absolute ethanol and fractions were counted in an HPGe
detector. The vial containing maximum radioactivity was diluted to a 5 % solution by
addition of normal saline. The active solution was checked for radiochemical purity by
polymer-backed silica gel layer chromatography using dry ethyl acetate as the mobile
phase. The final solution was then passed through a 0.22-mm filter and pH was adjusted
to 5–7 by adding 3 mol L–1 sodium acetate buffer.
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Quality control of 61Cu-ATSM
Radio thin layer chromatography. – A 5-mL sample of the final fraction was spotted on
chromatography silica gel sheet paper and developed in a mixture of 10 % ammonium
acetate/methanol (1:1) as the mobile phase. Alternatively, 10 mmol L–1 diethylenetri-
aminepentaacetic acid (DTPA) solution can be used as another mobile phase to discrimi-
nate free copper from the radiolabeled compound.
High performance liquid chromatography. – HPLC was performed in the final prepara-
tion using a mixture of water/acetonitrile 1:1 (V/V) as the eluent (flow rate: 1 mL min–1,
pressure: 1275 N m–2) for 20 min, in order to elute low molecular mass components.
Radiolabeled compound was eluted using the reverse stationary phase. Any remaining
free Cu2+ cation with chloride or acetate counter ion was eluted at the same time.
Stability of [61Cu]ATSM complex
Stability tests were based on previous studies performed for radiolabeled copper
complexes (18). A sample of [61Cu]ATSM (185 MBq) was kept at room temperature for 5
hours and checked by RTLC every half-an-hour. A micropipet sample (5 mL) was taken
from the shaking mixture and the ratio of free radiocopper to [61Cu]ATSM was checked
by radio thin layer chromatography (eluent: dry ethyl acetate).
Serum stability studies
To 36.1 MBq of [61Cu]ATSM, 500 mL of freshly prepared human serum was added
and the resulting mixture was incubated at 37 °C for 5 hours. Aliquots (5-mL) were ana-
lyzed by radio-TLC after 0, 0.25, 0.5, 1, 2 and 3 hours of incubation to determine the sta-
bility of the complex.
Biodistribution of [61Cu]acetate and [61Cu]ATSM in normal rats
Mature male NMRI rats (Razi Institute, Iran), weighing 150–250 g were used in ex-
periments. The animals were kept in groups of ten, in cages under constant temperature
(24 °C) and 12 h light/dark schedule. They had free access to the standard rat diet and
water except during the experiment. On the day of the experiment, animals were ran-
domly transferred to individual cages and allowed to acclimatize for 30 min before in-
jection of tracer and free copper cation. [61Cu]acetate and [61Cu]ATSM were adminis-
tered to separate normal rat groups. A volume (50 mL) of [61Cu]ATSM or [61Cu]acetate
solutions containing 37 MBq radioactivity were injected intravenously to rats via tail
veins. The animals were sacrificed at exact time intervals (1 and 2 h for [61Cu]acetate
and 30–210 minutes for [61Cu]ATSM), and the injected dose ID was calculated as per-
centage (based on area under the curve of 283 keV peak) per gram of different tissue us-
ing an HPGe detector.
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Co-incidence imaging studies
The final [61Cu]ATSM solution of 1.85 MBq activity (0.1 mL) was injected into the
dorsal tail vein of healthy rats. The total amount of radioactive material injected into
each rat was measured by a counting 1-mL syringe before and after injection in an activ-
ity meter with fixed geometry. The animals were relaxed by halothane and fixed in a
suitable probe. Images were taken 1, 2 and 3 hours after administration of the radiophar-
maceutical in the coincidence mode of a Dual-Head SPECT system (SMV, Sopha DST-XL,
Sopha, France). The useful field of view (UFOV) was 540 mm ´ 400 mm. The spatial reso-
lution in the coincidence mode was 10 mm full width at half maximum (FWHM) in the
central field of view (CFOV), and sensitivity was 0.320 counts s–1 Bq–1 mL–1. Sixty four
projections were acquired for 30 seconds per view with a 64 ´ 64 matrix. Each rat was
studied for 3 hours during which time images were taken every 60 minutes.
RESULTS AND DISCUSSION
For 76-min bombardment of the natZn target with 22 MeV proton, 150 mA the result-
ing activity of 61Cu was 222 GBq at the end of bombardment (EOB) and the production
yield was 440 MBq mA–1 h–1. Yield from the radiochemical separation was more than 95 %.
Quality control of the product was performed in two steps. Radionuclidic control sho-
wed the presence of 67.41 (4.2 %), 282.96 (12.2 %), 373 (2.2 %), 511 (122.9 %), 656 (10.8 %),
1186 (3.8 %) keV g-rays from 61Cu and showed a radionuclidic purity of 99 % at the end
of synthesis (EOS). The rest of activity was attributed to 60Cu (0.23 %). In order to check
the chemical purity, concentrations of zinc (from target material) and gold (from target
support) were determined using visible colorimetric assays. The presence of zinc cations
was checked by visible colorimetric assays. Even at 1 mg kg–1 of standard zinc concen-
tration, the pinkish complex was visible by naked eye, while the test sample remained
similar to the blank. The colorimetric assay demonstrated that the zinc cation concentra-
tion was far below the maximum permitted levels, i.e., 5 mg kg–1 (less than 1 mg kg–1
zinc). The gold concentration was less than 0.9 mg kg–1.
[61Cu]ATSM is a neutral, lipophilic compound that can penetrate all the cells with
perfusion. However it structure changes due to the reduction of Cu2+ cation to Cu+ cat-
ion in hypoxic conditions resulting in hypoxic cell accumulation. Fig. 1 shows the chemi-
cal structure of [61Cu]ATSM.
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NHCH3 Fig. 1. Structural formula for [61Cu]ATSM.
In TLC studies, the more polar free compound and free copper correlate to smaller
Rfs (Rf = 0.1–0.2) (Fig. 4), while the [61Cu]ATSM complex migrates with higher Rf (Rf = 0.9).
In all radiolabeling runs (n = 9) (Fig. 5), the integral ratio of the Cu-ATSM and free Cu
peaks was constant (98:2), showing the high radiochemical purity and consistency of the
labeling method.
In order to obtain the best labeling reaction conditions, the complex formation was
studied for temperature dependence. Heating the reaction mixture to 50 °C did not in-
crease the yield, but resulted in various unknown radiochemical impurities. Thus, 25 °C
was considered as the optimum temperature.
In HPLC studies, the fast eluting compound was shown to be hydrophilic [61Cu]Cu2+
cation (2.01 min), while the lipophilic [61Cu]ATSM complex was eluted a few minutes
later (6.22). In various studies, n = 9, the purity of both radiochemical spieces was shown
to be 100 %, as shown in Fig. 3.
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Fig. 2. RTLC of the start-
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Fig. 3. HPLC for [61Cu]Cu2+ (in acetate and chloride form, left) and [61Cu]ATSM (right) using a re-
verse phase column with a mixture of H2O:CH3CN (1:1) as eluent.
The final radiolabelled complex diluted in normal saline was then passed through a
0.22-mm (Millipore, USA) filter for sterilization. Due to its thermal instability, [61Cu]ATSM
preparation could be totally degraded and left detectable amounts of free copper after
autoclaving. Incubation of [61Cu]ATSM in freshly prepared human serum for 3 hours at
37 °C showed no loss of 61Cu from the complex at least for 2.5 hours.
RTLC was performed, using a mixture of dry ethyl acetate as the mobile phase to
control the radiochemical purity of the product.
Total labeling and formulation of [61Cu]ATSM took about 5 minutes, with a yield of
98 %. No labeled by-products were observed upon RTLC analysis of the final prepara-
tions after C18 solid phase purification. [61Cu]ATSM was stable in aqueous solutions for
at least 24 h as detected by RTLC (radiochemical purity 98 %).
In order to investigate biodistribution of [61Cu]ATSM in our animal models we had
to obtain the biodistribution data for free copper cation. Thus after injection of 1.48 MBq
of the [61Cu]CuCl2 pre-formulated by the normal saline (pH. 6.5–7), through the tail vein
of adult rats, the biodistribution of the cation was checked in various vital organs. How-
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Fig. 4. Calculated ID g–1 (%) of: a) [61Cu]CuCl2 and b) [61Cu]-ATSM in normal rats (n = 5).
ever, the copper is partly accumulated in liver as a reservoir for many metals especially
copper by serum ceruloplasmin. Gastrointestinal (GI) accumulation especially in the first
hour is expressed as a result of liver secretion via hepatobilliary excretion, while it is not
significant after 2 hours. The major content of copper is washed out by kidneys and con-
sequently urinary tract. The uptakes of rest of the tissues are not significant.
As shown in Fig. 4, due to lipophilicity of [61Cu]ATSM, it is rapidly washed out from
blood stream while easily peneterates into phospholipid bilayer of cells. The compound
has a slight liver uptake which is common for most of Cu-thiosemicarbazones.
Interestingly, 61Cu-ATSM was highly accumulated in the lungs starting from 30 mi-
nutes up to 210 minutes (Fig. 4).
Regarding the lung as a metabolic organ, the presence of various reductases and es-
pecially matrix metalloproteinases in this tissue can be a cause of tracer retention since
the Cu2+/Cu+ reduction can produce Cu(I)ATSM– in charged form, without the ability
of crossing the phospholipid bilayer of the cell membrane (19).
Administration of the tracer to fibrosarcoma-bearing rats showed high uptake in the
liver, stomach, intestine, suggesting a hepatobiliary excretion model. The lung uptake
was significant as discussed in normal animal distribution.
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Fig. 5. Calculated ID g–1 (%)
of [61Cu]ATSM 30–180 mi-





Fig. 6. Co-incidence images for 61Cu-
-ATSM uptake of a fibrosarcoma-bear-
ing rat 60 minutes post injection.
Biodistribution of the tracer was checked in normal and tumor-bearing animals for
up to 3 hours. Significant accumulation also took place in kidneys and fibrosarcoma in
all animals.
As mentioned earlier Cu-ATSM is a hypoxic cell targeting agent. The tumor uptake
was high in some parts at all time intervals and the level of uptake remained constant.
Since all tumor parts may not necessarily be hypoxic in the counting experiments, the
tumors were cut into pieces and various parts were counted.
The distribution of more than 1.5 % could be enough to perform imaging studies
(Fig. 5). The best time period for scanning was found to be 1 to 2 hours post injection; up
to 2 hours post injection rather high accumulation was observed in the liver and GI sys-
tem of the rats.
In order to visualize the tissue and tumor uptake in the administered mice, a co-in-
cidence image was taken, while the deceased animal body was shown with the tumor
body shown on the right (Fig. 6). While the whole tumor volume was 10 cm3, only slight
parts of tumor demonstrated the hypoxic imaging agent uptake. Thus, 60–120 min was
confirmed to be the best acquisition time post tracer injection.
CONCLUSIONS
[61Cu]ATSM is a PET radiopharmaceutical for hypoxia imaging with an intermedi-
ate half-life. The co-incidence imaging in the tumor-bearing animals showed the specific
tumor uptake of copy in parts of the tumor. Our future experiments on this radiophar-
maceutical will focus on other tumor models and finally PET studies in humans.
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S A @ E T A K
Predklini~ke studije [61Cu]ATSM kao PET radiofarmaka za snimanje fibrosarkoma
AMIR R. JALILIAN, NIMA ROSTAMPOUR, PEJMAN ROWSHANFARZAD, KAMALEDDIN SHAFAII, MOHSEN
KAMALI-DEHGHAN, MEHDI AKHLAGHI i MOHAMMAD B. TAVAKOLI
[61Cu]diacetil-bis(N4-metiltiosemikarbazon) ([61Cu]ATSM) dobiven je iz liganda di-
acetil-bis(N4-metiltiosemikarbazona) (ATSM) pripravljenog u vlastitom laboratoriju i
[61Cu]CuCl2 dobivenog iz natZn(p,x)61Cu (180 µA protonskim zra~enjem, 22 MeV, 3,2 h).
54
A. R. Jalilian et al.: Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging, Acta Pharm. 59 (2009)
45–55.
[61Cu]ATSM je ~i{}en ionskom kromatografijom. Prema HPLC i RTLC radiokemijska ~is-
to}a bila je > 98 %. [61Cu]ATSM je davan zdravim glodavcima i glodavcima s tumorom
tijekom 210 minuta te je pra}ena biodistribucija. @rtvovanjem testiranih `ivotinja te sni-
manjem primije}ena je zna~ajna razlika u akumulaciji [61Cu]ATSM u tumorskom tkivu u
odnosu na zdravo tkivo. [61Cu]ATSM je pogodan za dijagnostiku hipoksije tumora po-
zitron emisijskom tomografijom (PET).
Klju~ne rije~i: radiofarmak, bakar-61, [61Cu]ATSM, hipoksija, pozitronska tomografija, fibrosarkom,
snimanje
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